Bio-IT World Contributed Commentary | The global pharmaceutical industry is at a crossroads. It is, therefore, imperative for pharma organizations to reimagine their research value chain, in order to accelerate product innovation, and boost molecule pipelines during the discovery stage.
Aug 25 | Forbes | Denali Therapeutics, the stealthy South San Francisco biotech startup that raised $217 million last year to fight Alzheimer's, Parkinson's and ALS, is finally lifting the curtain on its plans this morning.
Aug 22 | Nature News & Comment | Ambitious bids to map the brain and cure cancer have not boosted overall research funding.
Aug 22 | Forbes | Pfizer says it will purchase biotechnology upstart Medivation for $14 billion in cash. The main prize in the deal: Medivation's prostate cancer drug, Xtandi, which costs $120,000 a year.
Aug 19 | Bio-IT World “Something that the industry doesn’t really talk about is the cost of doing research,” says Amrit Chaudhuri, CEO of Mass Innovation Labs in Cambridge, Mass. Running a lab can cost hundreds of dollars per square foot, Chaudhuri says, but Mass Innovation Labs offers an alternative.
Aug 18 | STAT | The gloves are off in the legal fight over CRISPR genome editing patents, as the latest documents filed in the case make clear.
Aug 17 | Nature News & Comment | Catalogue of genetic information from some 60,000 people reveals unexpected surprises - and highlights the need to make genomic data publicly accessible to aid studies of rare diseases.
Aug 17 | Computerworld | The chances of Apple's using Intel's factories to have its iPhone and iPad chips made have just rocketed up.
Aug 16 | Nature News & Comment | Technique that adds noise to genetic data would enable much faster access to large data sets.
Aug 16 | Forbes | Researchers describe a new way to use CRISPR editing to fix sickle cell disease, a debilitating genetic blood disorder.
Aug 16 | Xconomy | This startup sits at the intersection of electronics, optics, energy efficiency, and the Internet. Ayar Labs is working on how to make data centers perform better with less energy.
Aug 11 | Nature News | The surge of activity in recent years around CRISPR-Cas9 gene editing has also led to a flurry of modified CRISPR systems, or new systems entirely, which are starting to solve problems like delivering enzymes into cells, making specific changes to the DNA sequence, and editing RNA as well as DNA.
Aug 10 | Computerworld | Intel is buying Nervana Systems, a deep learning startup based out of California. The deal speaks volumes about Intel's hopes for the future and where the company is going.
Aug 10 | Bio-IT World | As the Genome Analysis Toolkit, developed at the Broad Institute, continues to serve as the standby for parsing raw genomic data in public projects and major institutions, members of the Broad speak to Bio-IT World about forthcoming updates in GATK4 and new ventures incorporating the toolkit.
Aug 09 | Fast Company | The school will adopt the Google Genomics cloud platform to improve how it treats patients with cancer, as well as to diagnose children with mysterious, rare diseases.
Aug 08 | Bio-IT World | Software company Repositive aims to make PDX mice, crucial animal models for studying human-like cancers, searchable across vendors by indexing hundreds of different repositories in one platform.
Aug 04 | The Seattle Times | Cray CEO Peter Ungaro considers the slowdown in the supercomputer market as "temporary."
Aug 03 | Forbes | Biotech and pharmaceutical industry professionals are busy people like everyone else. But they still find time to read books, especially when schedules slow down a tad during summer. So what are biotech professionals reading, and recommending, these days?
Aug 03 | Bio-IT World Briefs | Editas Medicine and Massachusetts General Hospital (MGH) announced an exclusive licensing agreement this morning, under which Editas can access intellectual property and technology related to high-fidelity Cas9 nucleases and Cas9 PAM variants that will enable the company to address an expanded range of genetically-defined diseases with the potential for enhanced specificity.
Aug 03 | Nature News & Comment | Daniel Himmelstein built a free online network to meld data from 28 public sources on links between drugs, genes, and diseases. Then he spent months chasing legal permission to republish the online data sets.